Irish Haematology Oncology Podcast

Pharmacology of SACT (Part 2)

Irish Haematology Oncology Podcast

Show Notes

In this episode, Eoin Tabb takes you beyond traditional chemotherapy, exploring the fascinating world of targeted therapies and immunotherapy. Learn how these cutting-edge treatments are revolutionizing cancer care by precisely targeting cancer cells and harnessing the power of the immune system. Discover the different types of targeted therapies and immunotherapies, their mechanisms of action, and their potential to improve patient outcomes.

Key Points:

Targeted Therapies:

Precision medicine approach

Targets specific vulnerabilities in cancer cells

Often fewer side effects than traditional chemotherapy

Types of Targeted Therapies:

Tyrosine Kinase Inhibitors (TKIs)

Block communication networks within cancer cells

Examples: Imatinib (CML), Erlotinib, Gefitinib (lung cancer)

Monoclonal Antibodies

Harness the immune system, block growth signals, or deliver toxic payloads

Examples: Rituximab (lymphoma), Trastuzumab (breast cancer), Cetuximab (colorectal/head and neck cancers)

Hormonal Therapies

Disrupt hormone supply lines in hormone-dependent cancers

Examples: Tamoxifen (breast cancer), Aromatase inhibitors (breast cancer), Androgen blockers (prostate cancer)

Antibody-drug conjugates (ADCs)

Combine targeting ability of antibodies with potent cell-killing drugs

Examples: Trastuzumab emtansine (breast cancer), Brentuximab vedotin (lymphoma)

Proteasome Inhibitors

Clog the cellular recycling system in cancer cells

Examples: Bortezomib, Carfilzomib, Ixazomib (multiple myeloma/lymphoma)

Immunotherapy:

Empowers the immune system to fight cancer

Types of Immunotherapy:

Immune Checkpoint Inhibitors

Release the brakes on the immune system

Examples: Ipilimumab, Nivolumab, Pembrolizumab, Atezolizumab

Adoptive Cell Transfer (ACT)

Supercharges immune cells to target cancer

Example: CAR-T cell therapy

Bispecific T-cell Engagers (BiTEs)

Bridge immune cells and cancer cells for targeted attack

Example: Blinatumomab

Cancer Vaccines

Teach the immune system to recognize and destroy cancer cells

Additional Notes:

Targeted therapies require specific biomarkers to be effective.

Immunotherapies are effective in certain cancers but can have unique side effects.

Ongoing research is expanding the use of targeted therapies and immunotherapies.

CPD IIOP Example: https://docs.google.com/document/d/1yd3jZv6upddu2V2qP61WdD7xE8joOXHR6ISQ4BNmIGY/edit?usp=sharing

Feedback Form: https://forms.gle/ebaoNCNe9Hg2fAMk6

More from Irish Haematology Oncology Podcast

Apr 6, 2025

Eoin Tabb reports from Day 3 of the ISOPP CAPhO 2025 Symposium in Victoria, Canada. This episode delves into crucial discussions on Equity, Diversity, and Inclusion (EDI) in pharmacy practice, the benefits and risks of Artificial Intelligence (AI) in oncology, updates on preventing Cancer-Associated Thrombosis (CAT), and the implementation of pre-therapeutic Pharmacogenomics (PGx), including combining DPYD testing with Therapeutic Drug Monitoring (TDM) for 5-FU. Plus, hear exciting news from the ISOPP AGM about next year's unique 24-hour virtual conference format and a special collaboration with the Irish Pharmacy Haematology Oncology Society (IPHOS)! #ISOPPCAPhO2025 #OncologyPharmacy #Haematology #ClinicalPharmacy #EDI #AI #PGx #TDM #CAT CAT Survey: https://redcap.alfredhealth.org.au/redcap/surveys/index.php?s=dFo7DpNgVBauTYeW&__startover=1

Apr 5, 2025

Join Eoin Tabb for the second daily dispatch from the ISOPP CAPhO 2025 Symposium in Victoria, Canada. Day 2 covered a wide spectrum of crucial topics for haematology/oncology pharmacy practice. Highlights include practical management strategies for PARP inhibitors, the importance of cultural humility and discussing traditional medicines, ISOPP's new global service level framework, pharmacy's role in disaster preparedness and environmental sustainability, efficiencies in myeloma treatment administration (pre-meds, infusion times, schedules), managing CMV infections, considerations for treating older/unfit patients using geriatric assessment, and critical updates on hazardous drug lists and safety. Tune in for key insights and takeaways relevant to Irish practice! #ISOPPCAPhO2025 #OncologyPharmacy #Haematology #ClinicalPharmacy PARPi Clinical Resource: https://cdn.ymaws.com/www.cano-acio.ca/resource/resmgr/endorsements/en_parp_inhibitor_clinical_r.pdf

Apr 4, 2025

Join host Eoin Tabb for a special dispatch episode recorded live from the ISOPP 2025 Symposium in Victoria, BC. Get your 'audio delegate bag' with key insights from Day 1, covering:

See all episodes →